Boston Scientific Corp. Fourth Quarter Earnings Sneak Peek

S&P 500 (NYSE:SPY) component Boston Scientific Corp. (NYSE:BSX) will unveil its latest earnings on Thursday, February 2, 2012. Boston Scientific provides devices used in medical procedures related to disciplines such as cardiology, endoscopy, gynecology, and electrophysiology.

Boston Scientific Corp. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 8 cents per share, a decline of 60% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 9 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 8 cents during the last month. For the year, analysts are projecting net income of 44 cents per share, a decline of 8.3% from last year.

Past Earnings Performance: Last quarter, the company beat estimates by 7 cents, coming in at profit of 15 cents a share versus the estimate of net income of 8 cents a share. It marked the fourth straight quarter of beating estimates.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: On average, analysts predict $1.91 billion in revenue this quarter, a decline of 4.5% from the year ago quarter. Analysts are forecasting total revenue of $7.68 billion for the year, a decline of 1.7% from last year’s revenue of $7.81 billion.

Analyst Ratings: Analysts seem relatively indifferent about Boston Scientific with 18 of 26 analysts surveyed maintaining a hold rating.

A Look Back: In the third quarter, profit fell 25.3% to $142 million (9 cents a share) from $190 million (12 cents a share) the year earlier, but exceeded analyst expectations. Revenue fell 2.2% to $1.87 billion from $1.92 billion.

Key Stats:

Revenue fell in the third quarter after seeing a rise the quarter before. In the second quarter, revenue rose 2.4%.

Competitors to Watch: Medtronic, Inc. (NYSE:MDT), St. Jude Medical, Inc. (NYSE:STJ), Merit Medical Systems, Inc. (NASDAQ:MMSI), C.R. Bard, Inc. (NYSE:BCR), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Stryker Corporation (NYSE:SYK), Teleflex Incorporated (NYSE:TFX), AngioDynamics, Inc. (NASDAQ:ANGO), and The Spectranetics Corp. (NASDAQ:SPNC).

Stock Price Performance: During December 28, 2011 to January 27, 2012, the stock price had risen 76 cents (14.7%) from $5.17 to $5.93. The stock price saw one of its best stretches over the last year between March 22, 2011 and March 30, 2011 when shares rose for seven-straight days, rising 6.2% (+43 cents) over that span. It saw one of its worst periods between November 11, 2011 and November 21, 2011 when shares fell for seven-straight days, falling 10.2% (-60 cents) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?